Fragile X Premutations, Mechanisms and Modifiers
脆性 X 前突变、机制和修饰因子
基本信息
- 批准号:10669025
- 负责人:
- 金额:$ 180万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-25 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:5&apos Untranslated RegionsAgeAntisense OligonucleotidesAreaBase SequenceBioinformaticsBiological ModelsCGG repeatCGG repeat expansionClinicalCollectionCoupledDNADataDevelopmentDiseaseEpigenetic ProcessFMR1FMRPFXTASFamilyFragile X GeneFragile X PremutationFragile X SyndromeFunctional disorderGene ModifiedGeneticGenetic TranscriptionGenomicsHaplotypesHumanImpairmentIndividualMammalsMediatingModelingMutationNeurodevelopmental DisorderNeuronsOnset of illnessOvarianPathogenicityPathologyPatientsPenetrancePharmacologic SubstanceProcessProductionProteinsRNAReproductive BiologyResearchResearch PersonnelResourcesRoleRunningSeriesSeveritiesSiteStructureSymptomsToxic effectTranslationsTremor/Ataxia SyndromeVariantWorkeffective therapygain of functiongenome wide screenhuman diseaseimprovedinsightmultidisciplinarynervous system disordernovelprimary ovarian insufficiencyreproductive system disorderrisk predictionrisk varianttargeted treatmenttherapeutic developmenttherapeutic targettherapy developmenttool
项目摘要
Fragile X Premutations- Mechanisms and Modifiers
Fragile X-associated disorders are a heterogeneous group of conditions arising from alterations
in the size, content, and epigenetic state of a polymorphic CGG repeat within the FMR1 gene.
Described as the first repeat expansion disorder nearly 30 years ago, FMR1 CGG repeat
expansions are both an important cause of neurological, reproductive and neurodevelopmental
disease as well as an archetype for understanding repeat expansions and the mechanisms by
which they elicit dysfunction. Work over past decades delineated the native functions of the
fragile X protein, FMRP, and the consequences of its loss and the explored toxic gain-of
function mechanisms (RNA-mediated toxicity via protein sequestration, and protein mediated
toxicity from Repeat associated non-AUG (RAN) translation) elicited by transcribed CGG
repeats. Despite these efforts, we still lack effective therapies for any of the cardinal Fragile X-
associated disorders.
Here we propose a paradigm shift in our approach to FX associated disorders. Rather than
focusing solely on specific diseases (Fragile X Syndrome (FXS), fragile X-associated
tremor/ataxia syndrome (FXTAS), and fragile X-associated primary ovarian insufficiency
(FXPOI)), the Center structure enables us to directly engage the mechanistic cross-talk between
conditions and between the FMR1 locus and related repeat expansion disorders. Our central
hypothesis is that a deeper understanding of genetic factors which underlie clinical disease
onset and penetrance in premutation associated disorders and an exploration of native CGG
repeat functions will reveal novel insights into both how repeats cause disease and how they
might be targeted therapeutically. Led by a multidisciplinary team featuring many leaders in the
Fragile X field, we will address this hypothesis in three cohesive projects all focused on
premutation disorders by using data-driven genomic and bioinformatics approaches coupled
with emerging tools and integrative model systems. By pooling our substantial data, expertise
and resources, we will pursue a deeper understanding of FX premutation pathogenic
mechanisms and define a series of robust and viable targets for therapeutic development
across Fragile X-associated disorders.
脆弱 X 前突变 - 机制和修饰符
脆性 X 相关疾病是由基因改变引起的一组异质性疾病
FMR1 基因内多态性 CGG 重复的大小、内容和表观遗传状态。
FMR1 CGG 重复被描述为近 30 年前第一个重复扩展障碍
扩张是神经、生殖和神经发育的重要原因
疾病以及理解重复扩张和机制的原型
它们会引起功能障碍。过去几十年的工作描述了
脆性 X 蛋白、FMRP 及其丢失的后果和探索的毒性增益
功能机制(RNA介导的通过蛋白质隔离的毒性,以及蛋白质介导的毒性)
由转录的 CGG 引起的重复相关非 AUG (RAN) 翻译的毒性
重复。尽管做出了这些努力,我们仍然缺乏针对任何主要脆性 X-
相关疾病。
在这里,我们建议对外汇相关疾病的治疗方法进行范式转变。而不是
仅关注特定疾病(脆性 X 综合征 (FXS)、脆性 X 相关疾病
震颤/共济失调综合征 (FXTAS) 和脆性 X 相关原发性卵巢功能不全
(FXPOI)),中心结构使我们能够直接参与之间的机械串扰
FMR1 基因座之间的条件以及相关的重复扩展障碍。我们的中央
假设是对临床疾病背后的遗传因素有更深入的了解
前突变相关疾病的发病率和外显率以及天然 CGG 的探索
重复功能将揭示重复如何引起疾病以及它们如何引起疾病的新见解
可能会成为治疗的目标。由多学科团队领导,其中包括许多领域的领导者
脆弱的 X 场,我们将在三个有凝聚力的项目中解决这个假设,所有项目都专注于
通过使用数据驱动的基因组和生物信息学方法耦合前突变疾病
具有新兴工具和集成模型系统。通过汇集我们的大量数据、专业知识
和资源,我们将追求对 FX 前突变致病性的更深入了解
机制并确定一系列稳健且可行的治疗开发目标
脆性 X 相关疾病。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Predictors of Comorbid Conditions in Women Who Carry an FMR1 Premutation.
- DOI:10.3389/fpsyt.2021.715922
- 发表时间:2021
- 期刊:
- 影响因子:4.7
- 作者:Allen EG;Charen K;Hipp HS;Shubeck L;Amin A;He W;Hunter JE;Shelly KE;Sherman SL
- 通讯作者:Sherman SL
Evaluation of AQP4 functional variants and its association with fragile X-associated tremor/ataxia syndrome.
- DOI:10.3389/fnagi.2022.1073258
- 发表时间:2022
- 期刊:
- 影响因子:4.8
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Loren Nelson其他文献
David Loren Nelson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Loren Nelson', 18)}}的其他基金
Baylor College of Medicine Intellectual and Developmental Disabilities Research Center
贝勒医学院智力与发育障碍研究中心
- 批准号:
10221022 - 财政年份:2020
- 资助金额:
$ 180万 - 项目类别:
Baylor College of Medicine Intellectual and Developmental Disabilities Research Center
贝勒医学院智力与发育障碍研究中心
- 批准号:
10085940 - 财政年份:2020
- 资助金额:
$ 180万 - 项目类别:
Fragile X Premutations, Mechanisms and Modifiers
脆性 X 前突变、机制和修饰因子
- 批准号:
10451592 - 财政年份:2020
- 资助金额:
$ 180万 - 项目类别:
Fragile X Premutations, Mechanisms and Modifiers
脆性 X 前突变、机制和修饰因子
- 批准号:
10271291 - 财政年份:2020
- 资助金额:
$ 180万 - 项目类别:
相似海外基金
Genomic and molecular determinants of EV-D68 neuroinvasive disease
EV-D68神经侵袭性疾病的基因组和分子决定因素
- 批准号:
10657198 - 财政年份:2023
- 资助金额:
$ 180万 - 项目类别:
Therapeutic Potential of Rescued FMR1 Mis-Splicing in Fragile X Syndrome
挽救 FMR1 错误剪接对脆性 X 综合征的治疗潜力
- 批准号:
10713600 - 财政年份:2023
- 资助金额:
$ 180万 - 项目类别:
Fluorescent IRE sensor for synucleinopathy drug discovery
用于突触核蛋白病药物发现的荧光 IRE 传感器
- 批准号:
10708197 - 财政年份:2022
- 资助金额:
$ 180万 - 项目类别:
Fluorescent IRE Sensor for Synucleinopathy Drug Discovery
用于突触核蛋白病药物发现的荧光 IRE 传感器
- 批准号:
10608833 - 财政年份:2022
- 资助金额:
$ 180万 - 项目类别: